<<The Flying Dutchman is a legendary ghost ship that can never make port and is doomed to sail the oceans forever. >> –Pedia, W.
Last November, a disspiriting diaspora of neuro talent from Bristol Myers Squibb began when BMS decided to disband its CNS research group; hence considerable surprise back in April, when the Ghost Ship signed its iPierian deal, acquiring that Company and its tau antibody program for $175 million upfront, and promises of much more later. But given that there are tauopathies that fall under the Rare Disease category, that seemed the probable angle for understanding a deal that was CNS-based, from a company that had seemingly chosen to exit the brain.
But today, it was announced that BMS is advancing a NR2B antagonist candidate molecule that had been developed within its ‘fully internalized’ alliance with NeurOp. They will be preparing the compound for its eventual IND, in psychiatry, aimed at Treatment-Resistant Depression. Which is not a rare disease.
One can only imagine what would be possible if they hadn’t made most of their crew walk the plank.